PMI
23.7.2020 16:50:09 CEST | Business Wire | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) has published the 10th issue of its Scientific Update , a regularly issued report on the company’s efforts to develop and scientifically assess a range of smoke-free alternatives to cigarettes.
PMI’s latest Scientific Update focuses on scientific evidence and the importance of relying on science to make decisions in a world too often clouded by personal and professional biases. It is guest-edited by Dr. Moira Gilchrist, Vice President Strategic & Scientific Communications at PMI.
“Humans can be terrible decision-makers, especially in the heat of the moment and when tensions are high,” Dr. Gilchrist explains. “Scientists in this field—whether working directly for tobacco companies or receiving funding from other sources—have a responsibility to take all necessary precautions to ensure our work is unbiased and accurate. This latest Scientific Update explains the research methodology PMI employs, which is aligned with that used by the pharmaceutical industry, and encourages all others working in this field to adhere to equally high standards.”
This issue also explores the latest research on smoke-free products published by PMI and independent analysts. It includes a review of 13 population health impact models , produced by PMI scientists in collaboration with leaders in tobacco harm reduction research. These models estimate how the health of a population could be affected by the presence or absence of smoke-free products in the market. The study—published in the peer-reviewed medical journal Nicotine & Tobacco Research —summarizes the strengths and weaknesses of the two approaches and demonstrates how future models can benefit from the inclusion of well-designed epidemiological study data. These findings will help to inform authorities as they consider various approaches to tobacco harm reduction.
Dr. Gizelle Baker, Director Global Scientific Engagement at PMI, answers common questions about heated tobacco products, explaining what they are and how they differ from cigarettes and e-vapor products and addressing common misconceptions about them. She describes several independent studies on unintended use recently reviewed on PMIScience.com , noting, “Generally, the data show that the population most likely to use electrically heated tobacco systems, are current smokers, with low uptake by youth and nonsmokers and a slightly higher but still low likelihood of uptake by former smokers.”
The recent decision by U.S. Food & Drug Administration (FDA) to authorize the marketing of PMI’s IQOS Tobacco Heating System as a Modified Risk Tobacco Product with reduced exposure information was a function of the U.S. law and also an example of a science-based approach to harm reduction. In the next issue, this topic will be explored in more detail.
The Scientific Update can be found at www.pmiscience.com/whats-new/scientific-update-10 .
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. For more information, please visit www.pmi.com and www.pmiscience.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200723005638/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 202629.7.2026 12:30:00 CEST | Press release
Compass Management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that it will release financial results for the second quarter and first half ended June 30, 2026, on August 5, 2026. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on August 5, 2026. A live webcast of the call will be available on the Compass Pathways website at: https://events.q4inc.com/attendee/246696001. The webcast will be archived for 30 days. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for tre
Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis29.7.2026 12:00:00 CEST | Press release
The European Commission approval is based on Phase 3b TRuE‑AD4 data which demonstrated that Opzelura® (ruxolitinib) cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24, and was well tolerated 1,2,3 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. "The European Commission's approval of Opzelura is an important milestone for adults in Europe living with moderate atopic dermatitis who need more treatment options," said Bill Meury, Chief Executive Officer, Incyte. "As the first steroid-free topical JAK inhibitor approved in the EU for atopic dermatitis, Opzelura offers an effective new treatment choice and reflects our commitment to advancing innovation for people with inflammatory
NTT DATA and ENGIE Announce Strategic Partnership to Power Sustainable AI and Data Center Growth29.7.2026 11:00:00 CEST | Press release
Multinational partnership to support sustainable expansion of NTT DATA’s global data center operations for AI, cloud and digital infrastructure growth.Long-term access to low-carbon and renewable energy with agreements already signed in UK, Germany and Netherlands.Power from RE100-compatible 24 MW wind farm in UK is already operational. NTT DATA, a global leader in AI, digital business and technology services, and ENGIE, a major player in the energy transition, today announced a strategic partnership to support the decarbonization, energy resilience and sustainable expansion of NTT DATA’s global data center operations. By combining ENGIE’s global leadership in renewable energy and low‑carbon solutions with NTT DATA’s infrastructure and technology services, the partnership secures long-term access to competitive renewable energy and power solutions that support the continued growth of NTT DATA’s data centers and AI infrastructure while addressing its net-zero ambitions. The partnership
Quectel Launches High-Performance FCM665D Module for Edge AI Applications29.7.2026 11:00:00 CEST | Press release
New high-performance module combines edge AI processing, Wi-Fi 6 and Bluetooth connectivity for smart home, smart building and industrial IoT applications Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the launch of the FCM665D, a high-performance Wi-Fi 6 and Bluetooth module with edge AI processing capabilities, designed for smart home, smart building and industrial IoT devices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729751874/en/ Quectel launches high-performance FCM665D module for edge AI applications Designed for products such as smart lighting, video doorbells and central control hubs, the FCM665D pairs high-performance connectivity with on-device intelligence, giving manufacturers a way to build faster, smarter, more capable devices without leaning on constant cloud connectivity. “This module has the AI capabilities and processing power to compete at the highest level
1NCE and Pessl Instruments Connect Smart Farms Worldwide29.7.2026 10:00:00 CEST | Press release
IoT specialists 1NCE and Pessl Instruments help farmers in 80 countries to connect and manage thousands of weather stations Smart farming solution improves water and fertilizer efficiency Both companies provide critical components at a 99.97% service availability 1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, and Pessl Instruments, a global leader in smart agriculture, announce today the roll-out of the METOS by Pessl Instruments weather network solution powered by 1NCE. The smart farming solution provided by Pessl Instruments connects thousands of weather stations and field sensors through a single platform, providing farmers real-time data of precipitation and soil moisture, extreme weather forecasting and crop disease risk in more than 80 countries. The main challenge for the deployment of smart farming solutions is always providing good coverage in rural areas. Thanks to 1NCE’s global connectivity service available in more
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
